But just like Smith, Klein, and French repackaged obesity as a psychological condition, a symptom of depression, Richard Wurtman wanted to label obesity as a killer, because if the alternative is death, then some risky side effects dont look so bad
Beginning July 1, 2026, eligible Medicare Part D beneficiaries will have access to Wegovy and Zepbound (specifically the KwikPen formulation) for weight loss at a flat $50 per month copay through a temporary program called the Medicare GLP-1 Bridge
Allegations in the Novo Nordisk A/S (NVO) Lawsuit According to the complaint, the lawsuit targets Novo Nordisk A/S and senior executives Maziar Mike Doustdar, Lars Fruergaard Jrgensen, Karsten Munk Knudsen, and David S
Retatrutide is one of the most promising upcoming medications for weight loss because of how powerfully it works across multiple metabolic pathways